PA8483101A1 - Compuestos quimicos - Google Patents
Compuestos quimicosInfo
- Publication number
- PA8483101A1 PA8483101A1 PA19998483101A PA8483101A PA8483101A1 PA 8483101 A1 PA8483101 A1 PA 8483101A1 PA 19998483101 A PA19998483101 A PA 19998483101A PA 8483101 A PA8483101 A PA 8483101A PA 8483101 A1 PA8483101 A1 PA 8483101A1
- Authority
- PA
- Panama
- Prior art keywords
- compounds
- purin
- amino
- chemical compounds
- phosphoramidates
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 abstract 1
- -1 NUCLEOSIDE PHOSPHORAMIDATES Chemical class 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000008298 phosphoramidates Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
SE DESCRIBEN COMPUESTOS QUÍMICOS QUE COMPRENDEN FOSFORAMIDATOS DE NUCLEÓSIDOS, SU PREPARACIÓN Y SU USO TERAPÉUTICO EN EL TRATAMIENTO DE INFECCIONES VIRALES, EN PARTICULAR HIV Y HBV. LOS COMPUESTOS CONTIENEN UN RESTO ANÁLOGO DE NUCLEÓSIDO ADENINA SUSTITUIDO QUE COMPRENDE 2-AMINO-6-(CICLOPROPILAMINO)-9H-PURIN-9-ILO. LOS COMPUESTOS PRESENTAN ACTIVIDAD ANTIVIRAL Y ESTABILIDAD FRENTE A LOS ÁCIDOS. SE INCLUYEN LAS SALES Y ÉSTERES DE LOS FOSFORAMIDATOS. UN COMPUESTO REPRESENTATIVO ES EL 5'- ¨(FENIL-(METOXI-L-ALANINIL)-FOSFORAMIDATO DE (1S,4R)-4(2-AMINO-6(CICLOPROPILAMINO)-9H-PURIN-9-IL)-2-CICLOPENTANO-1-METANOL.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9821058.6A GB9821058D0 (en) | 1998-09-28 | 1998-09-28 | Chemical compound |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8483101A1 true PA8483101A1 (es) | 2000-09-29 |
Family
ID=10839578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA19998483101A PA8483101A1 (es) | 1998-09-28 | 1999-09-27 | Compuestos quimicos |
Country Status (32)
Country | Link |
---|---|
US (1) | US6638919B2 (es) |
EP (1) | EP1117669B1 (es) |
JP (1) | JP2002525374A (es) |
KR (1) | KR20010085855A (es) |
CN (1) | CN1328565A (es) |
AR (1) | AR042368A1 (es) |
AT (1) | ATE231874T1 (es) |
AU (1) | AU762757B2 (es) |
BR (1) | BR9914097A (es) |
CA (1) | CA2345672A1 (es) |
DE (1) | DE69905181T2 (es) |
DK (1) | DK1117669T3 (es) |
ES (1) | ES2192081T3 (es) |
GB (1) | GB9821058D0 (es) |
GC (1) | GC0000174A (es) |
GT (1) | GT199900166A (es) |
HK (1) | HK1036455A1 (es) |
HU (1) | HUP0103641A3 (es) |
IL (1) | IL141959A0 (es) |
MA (1) | MA26694A1 (es) |
MY (1) | MY121839A (es) |
NO (1) | NO20011198L (es) |
NZ (1) | NZ510506A (es) |
PA (1) | PA8483101A1 (es) |
PE (1) | PE20001072A1 (es) |
PL (1) | PL346905A1 (es) |
PT (1) | PT1117669E (es) |
TN (1) | TNSN99183A1 (es) |
TR (1) | TR200100864T2 (es) |
TW (1) | TWI243176B (es) |
WO (1) | WO2000018775A1 (es) |
ZA (1) | ZA200102170B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002536452A (ja) * | 1999-02-12 | 2002-10-29 | グラクソ グループ リミテッド | 抗ウイルス剤としての(1R,cis)−4−(6−アミノ−9H−プリン−9−イル)−2−シクロペンテン−1−メタノールのホスホルアミダート、ならびに一、二および三リン酸エステル |
BR0012676A (pt) | 1999-07-22 | 2003-07-01 | Newbiotics Inc | Métodos para tratamento de tumores resistentes a terapia |
PE20010915A1 (es) * | 1999-12-10 | 2001-09-29 | Glaxo Group Ltd | Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales |
JP2003516408A (ja) * | 1999-12-10 | 2003-05-13 | グラクソ グループ リミテッド | 抗ウィルス薬としての(1R,シス)−4−[4−アミノ−7H−ピロロ(2,3−d)ピリミジン−7−イル]−2−シクロペンテン−1−メタノール類縁物 |
NZ536942A (en) | 2000-07-21 | 2006-03-31 | Gilead Sciences Inc | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
US8716548B2 (en) | 2002-02-20 | 2014-05-06 | The Procter & Gamble Company | Disposable absorbent article designed to facilitate an easy change |
US20030158532A1 (en) | 2002-02-20 | 2003-08-21 | Magee Luke R. | Disposable absorbent article designed to facilitate an easy intuitive change |
US7094768B2 (en) | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
KR20050059199A (ko) | 2002-09-30 | 2005-06-17 | 제네랩스 테크놀로지스, 인코포레이티드 | C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
RU2005118421A (ru) | 2002-11-15 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | 2'-разветвленные нуклеозиды и мутация flaviviridae |
GB0401088D0 (en) | 2004-01-19 | 2004-02-18 | Univ Cardiff | Phosphoramidate derivatives |
CA2571079A1 (en) * | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
EP1763521A1 (en) * | 2004-06-30 | 2007-03-21 | Eli Lilly and Company | 1- (indole-6-carbonyl-d-phenylglycinyl)-4- (l-methylpiperidin-4- yl) piperazine d-tartrate |
GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
GB0623493D0 (en) * | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
PL217694B1 (pl) | 2010-10-19 | 2014-08-29 | Inst Chemii Bioorg Polskiej Akademii Nauk | Analog nukleotydu, sposób otrzymywania analogu nukleotydu, zastosowanie analogu nukleotydu, pro-nukleotyd antywirusowy, kompozycja farmaceutyczna |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2013039920A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
CA2840242C (en) | 2011-09-16 | 2019-03-26 | Gilead Sciences, Inc. | Methods for treating hcv |
WO2013056046A1 (en) | 2011-10-14 | 2013-04-18 | Idenix Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
NZ702744A (en) | 2012-05-22 | 2016-12-23 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
WO2013174962A1 (en) | 2012-05-25 | 2013-11-28 | Janssen R&D Ireland | Uracyl spirooxetane nucleosides |
CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
AU2013329521B2 (en) | 2012-10-08 | 2018-04-19 | Centre National De La Recherche Scientifique | 2'-chloro nucleoside analogs for HCV infection |
EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
DK2950786T3 (da) | 2013-01-31 | 2020-02-17 | Gilead Pharmasset Llc | Kombinationsformulering af to antivirale forbindelser |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
US20140271547A1 (en) | 2013-03-13 | 2014-09-18 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
EP3004130B1 (en) | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
US20150037282A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
US10202411B2 (en) | 2014-04-16 | 2019-02-12 | Idenix Pharmaceuticals Llc | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV |
WO2016134058A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
CN113277985B (zh) * | 2016-07-20 | 2023-07-28 | 纳莹(上海)生物科技有限公司 | 一种荧光探针及其制备方法和用途 |
US20190185507A1 (en) * | 2016-08-19 | 2019-06-20 | Sandoz Ag | Sofosbuvir Derivatives for the Treatment of Hepatitis C |
RU2659388C1 (ru) * | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
EP3831388B1 (en) * | 2018-07-27 | 2024-02-28 | FUJIFILM Corporation | Cyclopentenyl purine derivative or salt thereof for use in suppressing adenovirus |
WO2020022487A1 (ja) | 2018-07-27 | 2020-01-30 | 富士フイルム株式会社 | シクロブチルプリン誘導体またはその塩 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0319228B1 (en) | 1987-11-30 | 1994-11-02 | Beecham Group Plc | Novel compounds |
CA2001715C (en) * | 1988-11-14 | 1999-12-28 | Muzammil M. Mansuri | Carbocyclic nucleosides and nucleotides |
MY104575A (en) * | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
EP0468119A1 (en) * | 1990-07-24 | 1992-01-29 | Merrell Dow Pharmaceuticals Inc. | Novel carbocyclic analogs of certain nucleosides |
SE9003151D0 (sv) * | 1990-10-02 | 1990-10-02 | Medivir Ab | Nucleoside derivatives |
EP0618214A1 (en) | 1993-04-01 | 1994-10-05 | Merrell Dow Pharmaceuticals Inc. | Unsaturated phosphonate derivatives of purines and pyrimidines |
DE69435319D1 (de) | 1993-09-17 | 2010-12-16 | Gilead Sciences Inc | Nukleotidanaloge |
GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
PL188660B1 (pl) | 1996-10-16 | 2005-03-31 | Icn Pharmaceuticals | Purynowe L-nukleozydy, ich analogi oraz zastosowanie |
-
1998
- 1998-09-28 GB GBGB9821058.6A patent/GB9821058D0/en not_active Ceased
-
1999
- 1999-09-22 TW TW088116280A patent/TWI243176B/zh active
- 1999-09-24 MA MA25787A patent/MA26694A1/fr unknown
- 1999-09-27 PL PL99346905A patent/PL346905A1/xx unknown
- 1999-09-27 AT AT99949151T patent/ATE231874T1/de not_active IP Right Cessation
- 1999-09-27 AU AU62138/99A patent/AU762757B2/en not_active Ceased
- 1999-09-27 ZA ZA200102170A patent/ZA200102170B/en unknown
- 1999-09-27 PT PT99949151T patent/PT1117669E/pt unknown
- 1999-09-27 IL IL14195999A patent/IL141959A0/xx unknown
- 1999-09-27 CN CN99813577A patent/CN1328565A/zh active Pending
- 1999-09-27 WO PCT/GB1999/003207 patent/WO2000018775A1/en not_active Application Discontinuation
- 1999-09-27 ES ES99949151T patent/ES2192081T3/es not_active Expired - Lifetime
- 1999-09-27 KR KR1020017003894A patent/KR20010085855A/ko not_active Application Discontinuation
- 1999-09-27 PA PA19998483101A patent/PA8483101A1/es unknown
- 1999-09-27 EP EP99949151A patent/EP1117669B1/en not_active Expired - Lifetime
- 1999-09-27 TN TNTNSN99183A patent/TNSN99183A1/fr unknown
- 1999-09-27 JP JP2000572234A patent/JP2002525374A/ja not_active Withdrawn
- 1999-09-27 HU HU0103641A patent/HUP0103641A3/hu unknown
- 1999-09-27 DE DE69905181T patent/DE69905181T2/de not_active Expired - Fee Related
- 1999-09-27 PE PE1999000978A patent/PE20001072A1/es not_active Application Discontinuation
- 1999-09-27 DK DK99949151T patent/DK1117669T3/da active
- 1999-09-27 BR BR9914097-7A patent/BR9914097A/pt not_active IP Right Cessation
- 1999-09-27 NZ NZ510506A patent/NZ510506A/en unknown
- 1999-09-27 CA CA002345672A patent/CA2345672A1/en not_active Abandoned
- 1999-09-27 MY MYPI99004169A patent/MY121839A/en unknown
- 1999-09-27 TR TR2001/00864T patent/TR200100864T2/xx unknown
- 1999-09-28 GT GT199900166A patent/GT199900166A/es unknown
- 1999-09-28 GC GCP1999302 patent/GC0000174A/en active
- 1999-09-28 AR ARP990104876A patent/AR042368A1/es not_active Application Discontinuation
-
2001
- 2001-03-08 NO NO20011198A patent/NO20011198L/no unknown
- 2001-03-27 US US09/825,554 patent/US6638919B2/en not_active Expired - Fee Related
- 2001-10-12 HK HK01107186A patent/HK1036455A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8483101A1 (es) | Compuestos quimicos | |
ES2131116T3 (es) | Analogos de nucleotidos enantiomericos antirretrovirales. | |
MX9204474A (es) | Analogos nucleosidos 1,3-oxatiolano. | |
FI20001231A (fi) | 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina | |
ES2133138T3 (es) | Nucleosidos terapeuticos. | |
ATE219366T1 (de) | Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b | |
DE10399025I1 (de) | Wirkstoffvorl{ufer von Phosphonaten | |
DK0513917T4 (da) | Antivirale kombinationer indeholdende nukleosidanaloger | |
DK1104436T3 (da) | Beta-L-2'-deoxy-nukleosider til behandling af hepatitis B-virus | |
BR9815166A (pt) | "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral" | |
ES2091750T3 (es) | Compuestos antivirales. | |
DK1224940T3 (da) | Flydende formuleringer af interferon-beta | |
ATE161267T1 (de) | Antivirales 4'-thio-pyrimidin-nukleosid | |
DK1280813T3 (da) | Antivirale pyrimidin-nukleosidanaloger | |
ATE74603T1 (de) | Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung. | |
FI954615A (fi) | Puriinien ja pyrimidiinien tyydyttämättömiä fosfonaattijohdannaisia | |
DK615788D0 (da) | Nucleosidforbindelser til anvendelse mod virale infektioner | |
DK0625158T3 (da) | Terapeutiske nucleosider af 2',3'-dideoxy-3'-fluorpurinrækken | |
ECSP993155A (es) | Compuestos quimicos | |
ES2063147T3 (es) | Compuestos antivirales. | |
ATE321561T1 (de) | Azidoderivate von beta-l-2'-nukleosiden zur hiv- infektionsbehandlung | |
FI943295A (fi) | Piliostigma thonningii -uutteet, niiden käyttö ja niitä sisältävät formuloinnit | |
CY1117836T1 (el) | Βητα-l-2'-δεοξυ-νουκλεοσιδια για την θεραπεια ηπατιτιδας β |